Relay Therapeutics (RLAY) Capital Expenditures (2019 - 2025)

Relay Therapeutics (RLAY) has 7 years of Capital Expenditures data on file, last reported at $1000.0 in Q4 2025.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $1000.0 in Q4 2025; TTM through Dec 2025 was $410000.0, a 79.68% decrease from a year earlier, with the FY2025 full-year figure at $410000.0, down 79.68% from the prior year.
• Capital Expenditures for Q4 2025 stood at $1000.0, up from -$1000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for RLAY reached as high as $3.4 million in Q4 2021 and fell as low as -$1.0 million in Q3 2021.
• Historically, Capital Expenditures has averaged $1.0 million across 5 years, with a median of $590000.0 in 2023.
• On a YoY basis, Capital Expenditures climbed as much as 833.33% in 2021 and fell as far as 341.11% in 2021.
• Year by year, Capital Expenditures stood at $3.4 million in 2021, then tumbled by 32.64% to $2.3 million in 2022, then sank by 94.91% to $118000.0 in 2023, then surged by 92.37% to $227000.0 in 2024, then sank by 99.56% to $1000.0 in 2025.
• Per Business Quant data, the three most recent Capital Expenditures figures were $1000.0 in Q4 2025, -$1000.0 in Q3 2025, and $26000.0 in Q2 2025.